Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVRiC
2024-518858-17-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AstraZeneca. Primary endpoint: Overall response rate. Planned start May 2026; status: authorised.
02
Drugs
acalabrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-518858-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518858-17-00.